Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBITDA (2016 - 2025)

Historic EBITDA for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$30.6 million.

  • Avalo Therapeutics' EBITDA fell 23261.28% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.8 million, marking a year-over-year decrease of 94469.66%. This contributed to the annual value of -$68.5 million for FY2024, which is 15049.18% down from last year.
  • Per Avalo Therapeutics' latest filing, its EBITDA stood at -$30.6 million for Q3 2025, which was down 23261.28% from -$20.8 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' EBITDA registered a high of $98.5 million during Q2 2024, and its lowest value of -$121.3 million during Q1 2024.
  • Moreover, its 5-year median value for EBITDA was -$13.1 million (2025), whereas its average is -$12.2 million.
  • Data for Avalo Therapeutics' EBITDA shows a peak YoY increase of 130179.42% (in 2024) and a maximum YoY decrease of 111838.27% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Avalo Therapeutics' EBITDA stood at -$18.0 million in 2021, then soared by 50.7% to -$8.9 million in 2022, then increased by 13.52% to -$7.7 million in 2023, then tumbled by 73.82% to -$13.3 million in 2024, then crashed by 129.51% to -$30.6 million in 2025.
  • Its last three reported values are -$30.6 million in Q3 2025, -$20.8 million for Q2 2025, and -$13.1 million during Q1 2025.